Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Saeed Sadeghi, M.D.
Saeed Sadeghi, M.D.


Hematology and Oncology

General Information:

English, Farsi, French


Associate Clinical Professor, Department of Medicine, Hematology/Oncology
Member, JCCC Community

Hospital Affiliation(s):

Ronald Reagan UCLA Medical Center
UCLA Medical Center, Santa Monica
Saint John's Health Center


Hematology-Oncology, UCLA School of Medicine, 2002 - 2005
Internal Medicine, LAC + USC Medical Center, 2000 - 2002
Internal Medicine, LAC + USC Medical Center, 1999 - 2000
Medical Degree:
M.D., Saint Louis University School of Medicine, 1999


Board Certification(s):
Hematology, American Board of Internal Medicine, 2009
Medical Oncology, American Board of Internal Medicine, 2006
Internal Medicine, American Board of Internal Medicine, 2003

Contact Information:

(310) 829 5471

Practice Information:

Clinical Interest(s):
Benign hematology
Breast cancer
Gastrointestinal tumors
Hepatobiliary tumors
Multiple myeloma
Ovarian and uterine cancers

Scientific Interest(s):

Dr. Saeed Sadeghi is interested in clinical trials, as a principal investigator or sub-investigator, in the area of breast and hepatobiliary cancer novel therapies.

Selected Cancer-Related Publications:

Khaledy C, Ashouri S, Hiyama D, Sadeghi S. Trastuzumab based Neoadjuvant Chemotherapy for Locally Advanced HER2 Over Expressing Gastric Adenocarcinoma. Proceedings of UCLA Healthcare 17: 1-4, 2013.

Tsang RY, Sadeghi S, Finn RS. Lapatinib, a Dual-Targeted Small Molecule Inhibitor of Egfr and Her2, in Her2-Amplified Breast Cancer: From Bench to Bedside. Clinical Medicine Insights: Therapeutics 3: 1-13, 2011.

Eiermann W, Pienkowski T, Crown J, Sadeghi S, Martin M, Chan A, Saleh M, Sehdev S, Provencher L, Semiglazov V, Press M, Sauter G, Lindsay MA, Riva A, Buyse M, Drevot P, Taupin H, Mackey JR. Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. J Clin Oncol. 2011 Oct 10;29(29):3877-84. doi: 10.1200/JCO.2010.28.5437. Epub 2011 Sep 12.

Sadeghi S, Wong SG. Targeting Angiogenesis in Ovarian Cancer, a brief review of Literature. Proceedings of UCLA Healthcare 15: 1-4, 2011.

Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S, Pegram M. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2009 Nov 20;27(33):5538-46. doi: 10.1200/JCO.2009.23.3734. Epub 2009 Sep 28.